Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,668.50
Bid: 1,668.00
Ask: 1,668.50
Change: -1.50 (-0.09%)
Spread: 0.50 (0.03%)
Open: 1,661.50
High: 1,679.50
Low: 1,658.50
Prev. Close: 1,670.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DIRECTOR DEALINGS: Glaxo Executives Acquire Shares, ADSs

Tue, 15th Apr 2014 15:08

LONDON (Alliance News) - GlaxoSmithKline PLC Tuesday said a group of executives, including Chief Executive Andrew Witty, acquired shares and American Depositary Shares under the 2009 deferred annual bonus plan at a price of 1581.50 pence per share and USD53.42 per ADS each following a dividend reinvestment.

Details are as follows.

Sir Andrew Witty

Acquisition of 2,101 Ordinary Shares under the personal contribution element of the Plan.

 

 

 

Acquisition of 2,101 Ordinary Shares under the matching element of the Plan (Company contribution).

 

 

Mr S Dingemans

Acquisition of 924 Ordinary Shares under the personal contribution element of the Plan.

 

 

 

Acquisition of 924 Ordinary Shares under the matching element of the Plan (Company contribution).

 

 

Dr M M Slaoui

Acquisition of 791 ADSs under the personal contribution element of the Plan.

 

 

 

Acquisition of 791 ADSs under the matching element of the Plan (Company contribution).

 

 

Mr S M Bicknell

Acquisition of 210 Ordinary Shares under the personal contribution element of the Plan.

 

 

 

Acquisition of 210 Ordinary Shares under the matching element of the Plan (Company contribution).

 

 

Mrs D P Connelly

Acquisition of 153 ADSs under the personal contribution element of the Plan.

 

 

 

Acquisition of 153 ADSs under the matching element of the Plan (Company contribution).

 

 

Mr R G Connor

Acquisition of 236 Ordinary Shares under the personal contribution element of the Plan.

 

 

 

Acquisition of 236 Ordinary Shares under the matching element of the Plan (Company contribution).

 

 

Mr S A Hussain

Acquisition of 119 Ordinary Shares under the personal contribution element of the Plan.

 

 

 

Acquisition of 119 Ordinary Shares under the matching element of the Plan (Company contribution).

 

 

Mr W C Louv

 

Acquisition of 191 ADSs under the personal contribution element of the Plan.

 

 

 

Acquisition of 191 ADSs under the matching element of the Plan (Company contribution).

 

 

Mr D S Redfern

Acquisition of 449 Ordinary Shares under the personal contribution element of the Plan.

 

 

 

Acquisition of 449 Ordinary Shares under the matching element of the Plan (Company contribution).

 

 

Ms C Thomas 

Acquisition of 338 Ordinary Shares under the personal contribution element of the Plan.

 

 

 

Acquisition of 338 Ordinary Shares under the matching element of the Plan (Company contribution).

 

 

Mr P C Thomson

Acquisition of 69 Ordinary Shares under the personal contribution element of the Plan.

 

 

 

Acquisition of 69 Ordinary Shares under the matching element of the Plan (Company contribution).

 

 

Mr D E Troy

Acquisition of 350 ADSs under the personal contribution element of the Plan.

 

 

 

Acquisition of 350 ADSs under the matching element of the Plan (Company contribution).

 

 

Dr P J T Vallance

Acquisition of 986 Ordinary Shares under the personal contribution element of the Plan.

 

 

Acquisition of 986 Ordinary Shares under the matching element of the Plan (Company contribution).

 

 

Ms E Walmsley

Acquisition of 544 Ordinary Shares under the personal contribution element of the Plan.

 

 

Acquisition of 544 Ordinary Shares under the matching element of the Plan (Company contribution).

 



Shares in the global healthcare company were trading at 1,549.00 pence up 0.4% Tuesday.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright © 2014 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.